Judges Scientific (JDG) AI Stock Analysis

• Market Cap: £339.68M
• Dividend Yield: 1.89%
• Average Volume (3M): 19.94K
• Price to Earnings (P/E): 30.2
• Beta (1Y): 0.61
• Revenue Growth: 5.46%
• EPS Growth: -26.44%
• Country: UK
• Employees: 767
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 1.39
• Shares Outstanding: 6,660,444
• 10 Day Avg. Volume: 25,550
• 30 Day Avg. Volume: 19,941
• PEG Ratio: 7.16
• Price to Book (P/B): 6.45
• Price to Sales (P/S): 4.20
• P/FCF Ratio: 25.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £4,825.50
• Price Target Upside: -5.38% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: 5,470.00p ▲(7.25% Upside)

Judges Scientific's strong financial performance and positive corporate events are significant strengths, contributing to a solid overall score. However, the stock's technical indicators suggest caution, and its high P/E ratio indicates potential overvaluation. The absence of recent earnings call data limits insights into current management sentiment and guidance.

Positive Factors

Cash generation

Judges Scientific demonstrates robust cash generation with growing free cash flow and a strong operating cash flow to net income ratio. This durable cash conversion supports reinvestment in R&D, funding of acquisitions, steady maintenance of service operations, and provides a buffer through business cycles over the next several quarters.

Diversified recurring revenue model

The company's mix of initial instrument sales plus consumables, service agreements and distribution channels creates recurring revenue streams. That diversification reduces reliance on one-time equipment orders, stabilises cash flow, and supports predictable post-sale margins and customer retention over a multi‑quarter horizon.

Strategic acquisitions and management action

Targeted acquisitions and recent leadership moves show active portfolio management and strategic intent to expand niche capabilities. Consolidating complementary tech and regional assets enhances market access and product breadth, supporting durable organic and inorganic growth beyond near‑term cycles.

Negative Factors

EPS contraction

A roughly 26% decline in EPS signals meaningful pressure on earnings power, which may reflect margin compression, restructuring or integration costs. Sustained EPS weakness reduces internal funding capacity and raises the bar for operational improvements, creating a multi‑quarter headwind to profit expansion.

Recent revenue decline

A recent dip in revenue interrupts top‑line momentum and could indicate softer end‑market demand or product cycle timing. If revenue growth does not reaccelerate, scalability of fixed costs and reliance on acquisitions to hit growth targets may increase, pressuring margins and long‑term organic growth prospects.

Moderate leverage / liabilities

The balance sheet shows moderate leverage, suggesting some reliance on debt financing. While manageable today, this constrains strategic flexibility for larger bolt‑on acquisitions or cyclical downturns, and raises refinancing and interest‑service risk that could materialise over the next several quarters if revenue or cash generation weakens.

Judges Scientific Business Overview & Revenue Model

Company Description

Judges Scientific plc designs, manufactures, and sells scientific instruments. The company operates through two segments, Materials Sciences and Vacuum. It offers engineering teaching and research equipment for universities, colleges, schools, and research centers; and research and development systems for food, beverage, dairy, edible oil, and pharmaceutical industries. The company also provides LED illumination systems for bioscience and clinical microscopy; tensile testing, motion control, and specimen cooling for microscopy applications; automated measurement systems for a range of fibers; edge-welded metal bellows; and fire testing instruments, such as cone calorimeters, large scale calorimeters, NBS smoke chambers and oxygen index test, and related fire testing instruments. In addition, it offers equipment and software used for the computer-controlled testing of soils and rocks; film deposition systems; physical and chemical vapour deposition instruments; open flow cryocoolers for the X-ray diffraction market and crycoolers for cooling applications, such as radio astronomy; test equipment for the characterization of optical fibers; scientific instruments primarily used for electron microscopy sample preparation; scientific equipment used by electrophysiology and imaging researchers; and gas purifiers for metal analysis. Further, the company provides specialized calorimeters used for chemical and battery industries; sample heating and manipulation products for use in vacuum markets for materials research and production; and sheet metalwork services, including components and casting, fabrication, bespoke engineering solutions, as well as laser cutting and CNC machining services. The company operates in the United Kingdom, rest of Europe, North America, China, and internationally. Judges Scientific plc was incorporated in 2002 and is based in London, the United Kingdom.

How the Company Makes Money

Judges Scientific generates revenue through the sale of its proprietary scientific instruments and equipment, as well as through ongoing maintenance and support services for these products. The company benefits from a diversified revenue model that includes direct sales to end-users, distribution partnerships, and potentially government contracts in research and development sectors. Key revenue streams include initial product sales, consumables, and service agreements, which provide recurring income. The company also engages in strategic acquisitions of niche technology firms, enhancing its product portfolio and market reach, thereby contributing to overall earnings growth.

Judges Scientific Financial Statement Overview

Summary

Judges Scientific exhibits strong financial management across all statements. The income statement reflects steady profitability, with some recent revenue challenges. The balance sheet is stable with manageable leverage, while the cash flow statement highlights excellent cash generation and liquidity. Continued focus on revenue growth and debt management could further enhance financial performance.

Income Statement

The company has shown solid gross profit margins, maintaining stable profitability over the years. The net profit margin is respectable, though there was a slight decline in revenue from 2023 to 2024. The EBIT and EBITDA margins are strong, indicating efficient operations. Overall, the income statement reflects a well-managed financial performance, but the recent revenue dip could be a concern.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, reflecting a balanced approach to leverage. The equity ratio indicates a solid foundation, though there is room for improvement in reducing liabilities. Return on equity is good, suggesting effective use of shareholder funds. The balance sheet is stable, but managing debt levels could enhance financial health further.

Cash Flow

The company demonstrates strong cash generation capabilities, with a positive operating cash flow to net income ratio. Free cash flow has grown steadily, indicating good financial management. The free cash flow to net income ratio supports a healthy cash conversion cycle, contributing to overall financial stability. The cash flow statement reflects robust liquidity and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	143.00M	133.60M	136.10M	113.21M	91.29M	79.86M
Gross Profit	23.30M	92.00M	93.60M	21.01M	15.34M	10.02M
EBITDA	31.80M	30.90M	32.20M	29.00M	20.33M	15.17M
Net Income	11.00M	10.40M	9.50M	12.50M	12.68M	8.22M
Balance Sheet
Total Assets	200.30M	205.10M	183.50M	185.79M	88.98M	82.03M
Cash, Cash Equivalents and Short-Term Investments	18.90M	17.90M	13.70M	20.83M	18.41M	15.52M
Total Debt	69.30M	73.60M	65.30M	59.95M	21.32M	26.37M
Total Liabilities	107.60M	117.90M	100.90M	131.33M	45.58M	48.98M
Stockholders Equity	92.50M	86.90M	82.40M	54.24M	42.78M	32.19M
Cash Flow
Free Cash Flow	28.40M	22.10M	20.60M	12.33M	13.44M	10.53M
Operating Cash Flow	32.80M	28.50M	26.50M	20.22M	16.89M	11.79M
Investing Cash Flow	-18.70M	-22.60M	-25.90M	-50.80M	-5.21M	-12.67M
Financing Cash Flow	-300.00K	-1.40M	-7.60M	31.20M	-8.81M	2.34M

Judges Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5100.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:JDG, the sentiment is Negative. The current price of 5100 is below the 20-day moving average (MA) of 5401.00, below the 50-day MA of 5513.60, and below the 200-day MA of 6448.68, indicating a bearish trend. The MACD of -166.30 indicates Positive momentum. The RSI at 39.89 is Neutral, neither overbought nor oversold. The STOCH value of 54.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:JDG.

Judges Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DSCV	77 Outperform	£596.91M	23.15	8.49%	2.09%	0.49%	61.73%
RSW	74 Outperform	£2.67B	32.09	9.15%	2.12%	3.15%	-13.57%
KMK	73 Outperform	£66.16M	5.21	7.39%	―	36.61%	―
JDG	69 Neutral	£339.68M	30.20	12.24%	1.89%	5.46%	-26.44%
GHH	67 Neutral	£196.52M	55.68	3.13%	2.19%	10.66%	21.19%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
TTG	54 Neutral	£218.66M	-3.12	-31.42%	―	-16.33%	-448.12%

Judges Scientific Corporate Events

Judges Scientific Updates Total Voting Rights to 6.66 Million Shares

Judges Scientific plc has reported that its total issued share capital stood at 6,660,444 ordinary shares of 5p each as of 31 January 2026, with no shares held in treasury and each share carrying one voting right. This updated figure, which establishes the company’s total voting rights, provides a new reference point for investors to assess and disclose notifiable shareholdings under regulatory transparency rules, ensuring accurate monitoring of ownership stakes and potential shifts in control.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5579.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific CEO Exercises Share Options, Lifting Issued Share Capital and Voting Rights

Judges Scientific plc has announced that its Chief Executive Officer, David Cicurel, has exercised options over 7,500 new ordinary shares, increasing his beneficial holding to 551,892 shares and his combined beneficial and non-beneficial interest to 618,892 shares, including a gifted stake held by the Shoftim Charitable Trust. As a result of this option exercise, the company’s issued share capital has risen to 6,660,444 ordinary shares, all carrying one vote each and none held in treasury, clarifying the new total voting rights figure for investors assessing notifiable interests under UK disclosure rules.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5470.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Grants New Share Options Tied to Earnings Growth Targets

Judges Scientific has granted options over 81,600 new ordinary shares under its 2025 share option schemes at an exercise price of £52.00, largely to its executive directors, as part of its policy to use equity incentives for retention and performance alignment. The bulk of the awards go to incoming chief executive Tim Prestidge, whose options, along with those granted to CFO Brad Ormsby and Group Commercial Director Ian Wilcock, will vest after three years subject to continued employment and the company delivering 5% compound annual growth in adjusted earnings per share, underscoring a pay structure tightly linked to medium-term earnings performance and leadership continuity.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5470.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Cuts Earnings Expectations as US Funding and Offshore Wind Slow Demand

Judges Scientific has warned that trading in 2025 fell short of expectations, as uncertainty over US federal funding for scientific research and weaker demand from offshore wind hit order intake and earnings, particularly in the United States where orders declined 23%. The group now expects adjusted earnings per share of about 275p for 2025, 6% below consensus, and is entering 2026 with a thinner order book and no Geotek coring expedition expected until early 2027; management has cut costs and is pushing geographic expansion and new product launches, but has set a cautious 2026 earnings guidance range of 200-250p on the assumption of no US recovery, underlining a more challenging near-term outlook for shareholders and operations despite continued solid cash conversion.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6301.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Receive Shares Through Incentive Plan Purchases

Judges Scientific has disclosed a series of small share purchases in the company by trustees of its Share Incentive Plan on behalf of senior management, including the chief executive officer, chief financial officer, chief operating officer, group business development director, group commercial director and group acquisition executive. The transactions, completed on 5 January 2026 on AIM at a price of 5,753p per ordinary share for volumes of three to four shares each, modestly increase management’s equity exposure and signal continuing alignment of key executives’ interests with those of shareholders, although the financial impact on the company’s capital structure is minimal.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6301.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Participate in Share Incentive Plan

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. The transactions, conducted on the London Stock Exchange’s AIM Market, reflect the company’s ongoing commitment to align management interests with shareholder value, potentially strengthening stakeholder confidence and market positioning.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £6301.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Acquires Remaining Stake in Geotek do Brasil

Judges Scientific has announced the acquisition of the remaining minority shareholding in its subsidiary Geotek do Brasil, which operates the core digitalisation business in Brazil. This acquisition, valued at an initial BRL13m (£1.9m), is expected to be immediately earnings enhancing for the group, indicating a positive impact on Judges Scientific’s financial performance and strengthening its position in the scientific instrument sector.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5871.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Announces Leadership Transition to Ensure Continued Growth

Judges Scientific has announced a significant board succession plan effective from February 2026. Founder and CEO David Cicurel will transition to Non-Executive Chair, while Tim Prestidge, currently the Group Business Development Director, will take over as CEO. This strategic leadership change is aimed at ensuring the continuity of the company’s successful acquisition strategy and long-term growth model. The transition is expected to maintain the company’s strong reputation and operational integrity, with Cicurel continuing to contribute his extensive experience in acquisitions. The leadership shift is designed to uphold shareholder value and the company’s commitment to ethical business practices.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5699.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Reinforce Commitment Through Share Purchases

Judges Scientific announced the purchase of ordinary shares by its Chief Financial Officer, Brad Ormsby, and Non-Executive Chairman, Ralph Elman, under an automatic dividend reinvestment program. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects ongoing confidence in the company’s financial health and strategic direction, potentially strengthening its market position and signaling positive implications for stakeholders.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5699.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Judges Scientific Executives Participate in Share Incentive Plan

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan, involving key executives including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects the company’s commitment to aligning management interests with shareholder value, potentially enhancing stakeholder confidence in the company’s strategic direction.

The most recent analyst rating on (GB:JDG) stock is a Hold with a £5699.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.